Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 265 participants.

Also called NCT05514548

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 265 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05514548
Other papers using this trial's data
  • A double-blind, randomized, placebo-controlled, phase 2 trial examined the efficacy and safety of monlunabant in adults with diabetic kidney disease Kidney international, 2026-06 DOI, PubMed 41866124

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Canada, Georgia, Hungary, Israel, Mexico, Serbia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05514548. Randomized; triple masking; primary purpose treatment. Start 2022-10-19 (actual); primary completion 2024-08-20 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease
Condition
Diabetic Kidney Disease
Intervention (Drug)
INV-202
Intervention (Drug)
Placebo
Lead sponsor
Inversago Pharma Inc. (class: industry)
Collaborator
Worldwide Clinical Trials (class: other)

Record details

Record id
cardio:ct-nct05514548
Content hash
3f1de5ccf3f4866be11bded7297ea9f854c7531218ed7cc097a0de87846f9eb8